Back to top
more

BioTechne Corp (TECH)

(Delayed Data from NSDQ)

$75.96 USD

75.96
649,382

-0.46 (-0.60%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $75.96 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Bayer (BAYRY) Files Applications in US & EU for Cancer Treatment

by Zacks Equity Research

Bayer (BAYRY) submits an sNDA in the United States and an MAA in Europe for the combo of copanlisib and rituximab to treat two types of cancer indication.

Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat

by Zacks Equity Research

Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.

Geron (GERN) Soars on Imetelstat Data for Myelofibrosis

by Zacks Equity Research

Geron (GERN) publishes data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory myelofibrosis. Stock rises.

Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies

by Zacks Equity Research

Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.

Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM

by Zacks Equity Research

The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.

Vertex's (VRTX) Trikafta Gets FDA Nod for CF in Children

by Zacks Equity Research

The FDA approves Vertex's (VRTX) triple combination therapy, Trikafta, for treating cystic fibrosis in children aged between six to 11 years.

Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE

by Zacks Equity Research

The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.

Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids

by Zacks Equity Research

The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.

bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold

by Zacks Equity Research

The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.

Techne (TECH) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Techne (TECH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Techne (TECH) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 19.33% and 7.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QGEN vs. TECH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

QGEN vs. TECH: Which Stock Is the Better Value Option?

Techne (TECH) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 19.12% and 9.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Techne (TECH) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 25.44% and 9.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia Completes Final Patient Treatment in Dry Eye Study

by Zacks Equity Research

Aurinia (AUPH) that it has completed the last patient study visit in the AUDREY study evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome.

Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer

by Zacks Equity Research

Celyad Oncology (CYAD) collaborates with Merck to evaluate its CAR-T candidate, CYAD-101,combined with the latter's Keytruda in microsatellite stable refractory metastatic colorectal cancer.

Alexion's Ultomiris Gets Approval in Japan for Rare Disease

by Zacks Equity Research

Alexion's (ALXN) Ultomiris gets approval in Japan for the treatment of adults and children living with atypical hemolytic uremic syndrome.

bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA

by Zacks Equity Research

The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.

Alexion's New Formulation of Ultomiris Gets CHMP Backing

by Zacks Equity Research

Alexion (ALXN) gets a positive opinion from the CHMP recommending marketing authorization for a new 100 mg/mL intravenous advanced formulation of Ultomiris in the EU.

Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab

by Zacks Equity Research

Agenus (AGEN) initiates the rolling submission of its BLA to the FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.

Immunomedics Releases Trodelvy Data From Cancer Studies

by Zacks Equity Research

Immunomedics (IMMU) releases data from different cancer studies on its lead drug, Trodelvy.